StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Thursday. The brokerage issued a sell rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $2.49 on Thursday. InspireMD has a one year low of $1.81 and a one year high of $3.77. The company has a market cap of $62.08 million, a price-to-earnings ratio of -3.28 and a beta of 0.91. The firm has a 50 day simple moving average of $2.73 and a 200 day simple moving average of $2.55.

InspireMD (NYSE:NSPR) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The firm had revenue of $1.74 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same quarter in the previous year, the company posted ($0.24) earnings per share. As a group, analysts expect that InspireMD will post -0.82 EPS for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD at the end of the most recent quarter. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.